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Background: Pressure ulcers represent a major burden to patients, carers and the healthcare system, affecting
approximately 1 in 17 hospital and 1 in 20 community patients. They impact greatly on an individual’s functional
status and health-related quality of life. The mainstay of pressure ulcer prevention practice is the provision of
pressure redistribution support surfaces and patient repositioning. The aim of the PRESSURE 2 study is to compare
the two main mattress types utilised within the NHS: high-specification foam and alternating pressure mattresses, in
the prevention of pressure ulcers.
Methods/Design: PRESSURE 2 is a multicentre, open-label, randomised, double triangular, group sequential, parallel
group trial. A maximum of 2954 ‘high-risk’ patients with evidence of acute illness will be randomised on a 1:1 basis
to receive either a high-specification foam mattress or alternating-pressure mattress in conjunction with an electric
profiling bed frame. The primary objective of the trial is to compare mattresses in terms of the time to developing
a new Category 2 or above pressure ulcer by 30 days post end of treatment phase. Secondary endpoints include
time to developing new Category 1 and 3 or above pressure ulcers, time to healing of pre-existing Category 2
pressure ulcers, health-related quality of life, cost-effectiveness, incidence of mattress change and safety. Validation
objectives are to determine the responsiveness of the Pressure Ulcer Quality of Life-Prevention instrument and the
feasibility of having a blinded endpoint assessment using photography. The trial will have a maximum of three
planned analyses with unequally spaced reviews at event-driven coherent cut-points. The futility boundaries are
constructed as non-binding to allow a decision for stopping early to be overruled by the Data Monitoring and
Ethics Committee.
Discussion: The double triangular, group sequential design of the PRESSURE 2 trial will provide an efficient design
through the possibility of early stopping for demonstrating either superiority, inferiority of mattresses or futility of
the trial. The trial optimises the potential for producing robust clinical evidence on the effectiveness of two
commonly used mattresses in clinical practice earlier than in a conventional design.
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Pressure ulcers (PUs) represent a major burden to pa-
tients, carers and the healthcare system affecting approxi-
mately 1 in 17 hospital and 1 in 20 community patients
[1–3]. They impact greatly on an individual’s functional
status and health-related quality of life as a consequence
of distressing symptoms including pain, exudate and
odour, increased care burden, prolonged rehabilitation,
requirement for bed rest, hospitalisation and for those
who work, prolonged sickness absence [4, 5].
The primary cause of a PU is mechanical load in the
form of pressure or pressure and shear, applied to soft
tissues, generally over a bony prominence. They range in
severity from non-blanchable erythema (Category 1),
superficial skin loss (Category 2) to severe ulcers involving
fat, muscle and bone (Category 3, 4 or unstageable) [6].
PU development is influenced by the intensity and
duration of pressure and occurs when the soft tissues
are unable to tolerate the sustained mechanical loads
that develop between bony prominences and a support
surface e.g. the sacrum and a mattress [7]. They are a
cross-specialty problem, a complication of serious acute
or chronic illness in patient populations characterised by
high levels of co-morbidity and mortality [8, 9].
The mainstay of PU prevention practice is the
provision of pressure redistribution support surfaces
(mattresses, cushions) and patient repositioning, to min-
imise both the intensity and duration of pressure expos-
ure of vulnerable skin sites, not adapted to sustained
and/or excessive loading [6, 7]. Pressure-relieving mat-
tresses either distribute the patient’s weight over a larger
contact area providing ‘constant low pressure’ or they
mechanically vary the pressure beneath the patient, so
reducing the duration of the applied pressure [10].
The two main mattress types utilised within the
National Health Service (NHS) are high-specification
foam (HSF) mattresses, which are classified as a ‘low-
tech constant low-pressure device’ and alternating-
pressure mattresses (APMs), which are classified as
‘high-tech’ support surfaces [10, 11]. Alternating pressure
mattresses are electrically powered and comprise large air-
filled pockets which inflate and deflate in cycles.
The conclusions of the updated Cochrane systematic
review [11] did not differ from the previous review [10].
The recent review concluded that foam alternatives tostandard hospital foam mattresses reduce the incidence
of pressure ulcers in patients at risk (RR 0.40 95% CI
0.21 to 0.74) [11]. One trial suggested that alternating-
pressure mattresses may be more cost-effective than
alternating-pressure overlays in a UK context [11].
However, the relative merits of APMs and constant low-
pressure devices remain unclear and recommended the
evaluation of APMs compared to constant low-pressure
devices such as HSF [11].
There is evidence that some patients do not like APMs
[12–14]. The alternating sensation is disliked by some
patients and can cause feelings of nausea and impact
upon sleep. In addition, upon patient movement, the air-
filled pockets are compressed and patients find it diffi-
cult to mobilise in bed and also report feeling unstable
at the mattress edge, either when they are getting in and
out of bed or feeling like they will be ‘rolled out of bed’,
creating an unsafe feeling [4, 12–14]. Other issues in-
clude noise from the pump, technical failure and attend-
ant alarms.
The National Institute for Health and Care Excellence
(NICE) guidance recommends the use of an HSF mat-
tress in adults who are admitted to secondary care and
who are assessed as being at high risk of developing a
PU in primary and community care settings [7]. HSF
mattresses are also recommended for adults with a PU,
and if this is not sufficient to re-distribute pressure, to
consider the use of a dynamic support surface [7].
Therefore the NICE guidance states that HSF is the
recommended ‘minimum’ standard of care for mattress
provision in the prevention and treatment of PUs. Des-
pite the large difference in the unit cost with HSF units
ranging from £180 to £600 and APM units ranging from
£1000 to £5000 and limited evidence of benefit of APMs
compared to HSF in PU prevention, they are in
widespread clinical use. This has been evidenced in the
National Institute of Health Research (NIHR) PURPOSE
pain cohort study where mattress allocation by ward
staff to a high-risk target population (mobility impaired
and/or Category 1 PU and/or pressure area-related pain)
was 48% HSF: 52% APM [15, 16], reflecting a lack of
standardised practice and clinical uncertainty relating to
mattress provision for ‘high-risk’ patients.
In light of the priority being given to PU prevention by
the NHS [7], the high cost and lack of evidence relating
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NHS, ad hoc practice in mattress allocation and the
disadvantages and difficulties reported by patients in the
use of APMs, we are undertaking a randomised con-
trolled trial (RCT) to compare HSF and APMs in a high-
risk in-patient population.
Objectives
The main aim of the study is to determine the clinical
and cost effectiveness of high-specification foam (HSF)
and alternating-pressure mattresses (APM) when both
are used in conjunction with an electric profiling bed
frame in secondary care and community in-patients
facilities in patients with evidence of acute illness, for
the prevention of Category 2 (and above) PU.
The primary objective is to compare the time to devel-
oping a new Category 2 or above PU, in patients using
HSF to those using APM by 30 days post end of treat-
ment phase.
The secondary objectives are:
1. To compare the time to developing a new Category
3 or above PU, between patients using HSF and
those using APM
2. To compare the time to developing a new Category
1 or above PU, between patients using HSF and
those using APM
3. To compare the time to healing of pre-existing
Category 2 PU between patients using HSF and
those using APM
4. To determine the impact of HSF and APM on
health-related quality of life
5. To determine the incremental cost-effectiveness of
APM compared to HSF from the perspective of the
health and social care sectors
6. To compare incidence of mattress change between
patients using HSF and those using APM
7. To compare safety between patients using HSF and
those using APM
Secondary validation objectives
1. To determine responsiveness of the Pressure Ulcer
Quality of Life-Prevention (PU-QoL-P) instrument
2. To assess the feasibility of a blinded outcome
assessment using photography and central blinded
endpoint review
Methods/Design
The PRESSURE 2 trial is a multicentre, open, rando-
mised, double triangular group sequential, parallel group
trial, with two planned interim analyses and validation
substudies.A maximum of 2954 ‘high-risk’ patients with evidence
of acute illness will be randomised to receive either HSF
or APM in conjunction with an electric profiling bed
frame from randomisation to the end of the treatment
phase (maximum 60 days), with a final assessment at 30
days post the end of treatment phase (Fig 1).
Study population
The multicentre trial will be conducted in acute secondary
care hospitals, community hospitals and NHS-funded
intermediate care/rehabilitation facilities in England and
Scotland. All participating centres have Tissue Viability
Nurse Specialists in post with hospital-wide remits to
establish pressure ulcer prevention guidelines, policies and
practice. Patients with evidence of acute illness will be
assessed for eligibility in accordance with the criteria
in Table 1.
Consent
Where eligibility is indicated by the attending clinical
team, patients will be flagged to a member of the hospital
Tissue Viability Team (TVT). A full verbal explanation of
the study Patient Information Leaflet (PIL) will be pro-
vided by a member of the TVT for the patient to consider.
Following information provision, patients will have as long
as they need to consider participation and will be given
the opportunity to discuss the study with their family and
other healthcare professionals before they are asked
whether they would be willing to participate in the study.
Assenting patients will be formally assessed for eligibility
and invited to provide informed consent.
For patients capable of giving consent but physically un-
able to complete the written aspects of the consent form,
witnessed consent will be provided by a family member or
friend of the patient, or another member of the patient’s
healthcare team who is not directly involved in the
research study using the Witnessed Consent Form.
A large proportion of patients at risk of pressure ulcers
have cognitive impairment affecting their understanding
of the trial and/or dementia. Cognition impacts upon
compliance with repositioning and self-care in the use of
the electric profiling functionality, which is an integral
component of the intervention package. It is important
that the trial population is representative of the normal
NHS patient population and therefore patients who lack
capacity will also be recruited onto the trial.
The assessment of capacity will relate specifically to
decisions pertaining to this particular research project.
Each patient will be assumed to have capacity unless it is
established that they lack capacity. Ward-based nurses
identifying patients for study participation will be asked to
consider aspects of capacity before any approach to
patients is made and during the information-giving stage
prior to consent. The TVT member will assess the
Fig. 1 Trial flow diagram
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make and why; the consequences of the decision to
participate; their ability to understand, use and retain the
information related to the decision to participate and be
able to communicate their decisions effectively (as speci-
fied in the Mental Capacity Act 2005). If there is any con-
cern about capacity the ward nurse/TVT member will
consult further with other members of the attending clin-
ical team and/or relative/carer/friend (as appropriate) and
a decision will be made with the relative/carer/friend as to
whether the patient is able to provide written consent.
Where the patient is thought not to have capacity to con-
sent, a relative, carer or friend who is interested in the pa-
tient’s welfare will act as a personal consultee or nearest
relative/guardian/welfare attorney (Scotland).
The relative/carer/friend will be involved in the infor-
mation and decision-making process with the patient
and will advise the TVT member on their presumedwishes and feelings and consultee or nearest relative/
guardian/welfare attorney (Scotland) assent will be ob-
tained on behalf of the patient. The relative, carer or
friend will be advised to set aside their own views and
provide advice on the participation of the patient in the
research, taking into consideration the patient’s wishes
and interests. Patients will not be required to do any-
thing which is contrary to any advance decisions or
statements that have been made by them in relation to
their treatment or any other matter. Advance decisions
made by the patient about their preferences and wishes
will always take precedence.
If, despite taking all reasonable steps, a personal
consultee cannot be identified and contacted then a nomi-
nated consultee or nearest relative/guardian/welfare attor-
ney (Scotland) would be approached. This person would
have no connection with the research project. They would
be nominated by the TVT member; they would most
Table 1 Inclusion and exclusion criteria
Inclusion criteria
1. Evidence of acute illness through:
a. acute admission to secondary care hospital, community hospital
or NHS-funded intermediate care/rehabilitation facility
b. secondary care, community hospital or NHS-funded intermediate
care/rehabilitation facility in-patient with onset of acute illness
secondary to elective admission
c. recent secondary care hospital discharge to community hospital
or NHS-funded intermediate care/rehabilitation facility
2. Aged ≥ 18 years
3. Have an expected total length of stay of 5 or more days
4. At high risk of PU development due to one or more of the
following:
a. bedfast/chairfast AND completely immobile/very limited mobility
(Braden activity score 1 or 2 and Mobility score 1 or 2) [20]
b. Category 1 PU on any pressure area skin site
c. localised skin pain on a healthy, altered or Category 1 pressure
area skin site
5. Consent to participate (written informed consent, witnessed verbal
consent, consultee agreement (England) or nearest relative/
guardian/welfare attorney (Scotland))
6. Expected to comply with the follow-up schedule
7. The patient is on an electric profiling bed frame
Exclusion criteria
1. Have previously participated in the PRESSURE 2 trial
2. Have a current or previous Category ≥3 PU
3. Have planned admission to ICU where standard care is
alternating-pressure mattress provision
4. Unable to receive the intervention (for example, sleep at night in a
chair or unable to be transferred to randomised mattress)
5. Patient weight is lower or higher than weight limits for HSF and
alternating-pressure mattresses (<45 kg/>180 kg)
6. It is ethically inappropriate to approach the patient
HSF high-specification foam, ICU intensive care unit, NHS National Health
Service, PU pressure ulcer
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est relative/guardian/welfare attorney (Scotland) would be
provided with the information leaflet describing the re-
search study and the role of the consultee/nearest relative/
guardian/welfare attorney and it would be emphasised
that they are being asked to act on behalf of the patient,
rather than on any personal views or feelings.
Where a patient has been enrolled into the study after
consultee or nearest relative/guardian/welfare attorney
(Scotland) agreement and they subsequently regain cap-
acity, a member of the research team will discuss the study
with the patient; provide a full verbal explanation of the
trial and a Patient Information Leaflet explaining the trial
and their participation in the trial. Assenting patients will
be invited to provide informed consent/witnessed ver-
bal consent for ongoing participation. Those who do not
wish to continue in the trial will be withdrawn.Consent for photographs to be taken of skin sites will
be obtained at time of consent to the trial with an opt-
out clause allowing patients to withdraw consent for
photographs at any time.
Patients who change from their allocated mattress will
continue follow-up assessments unless they are unwill-
ing to do so, and patients who withdraw from the trial
will continue to be managed in line with standard care.
Patients with capacity at study entry who subsequently
lose capacity will be withdrawn from the trial.
Randomisation
Following confirmation of informed consent, eligibility and
completion of baseline assessments, patients will be rando-
mised by an authorised member of the research team at
the site. Patients will be randomised in a 1:1 allocation ra-
tio, to receive either HSF or APM. Randomisation will be
performed using minimisation, incorporating a random
element, via a central 24-hour automated telephone ran-
domisation system based at the Leeds Institute of Clinical
Trials Research (LICTR). The dynamic allocation method
should ensure intervention groups are well balanced for
the following minimisation/stratification factors:
 Centre
 PU status (no pressure ulcer, Category 1, Category 2)
 Secondary care hospital, community hospital,
intermediate care or rehabilitation facility
 Method of consent (written OR witnessed verbal OR
consultee or nearest relative/guardian/welfare
attorney (Scotland) agreement)
The randomisation system will include an automated
internal check using NHS numbers to confirm that the
patient has not been recruited to the trial previously.
In addition, at the time of randomisation, 10% of pa-
tients will be randomly selected for expert clinical as-
sessment and photography.
Interventions
Patients will be randomised to either HSF or APM prod-
ucts used by the participating centre.
Specifications for both HSF and APM have been devel-
oped and mattresses are approved for inclusion in the trial
based on these specifications, as defined in a PRESSURE 2
Mattress Specification Guideline. The guideline for HSF
includes foam density (foam fatigue and foam hardness)
and mattress cover characteristics (removable, minimum
two-way stretch, vapour-permeable, covered zips) as de-
fined in BS 3379 [17] and for APMs includes minimum
and maximum values for cell height, cycle time and cycle
frequency [17]. All mattresses will comply with the Med-
ical Devices Regulations SI2002/618. The PRESSURE 2
Mattress Specification Guideline also provides details of
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combination mattresses e.g. static foam and alternating
cells, static foam and gel, hybrid alternating and low air
loss; and other continuous static low-pressure mattresses
including fibregel, fluid and air filled mattresses.
Trial-approved mattresses are identified at each centre
on an ongoing basis. After randomisation an eligible
mattress will be sourced and allocated by the Clinical
Research Nurse (CRN)/Registered Healthcare Professional
(RHCP). Mattress allocation is expected within 24 hours
of randomisation.
All patients will have an electric profiling bed frame as
an adjunct to the trial mattress.
Assessments/data collection and follow-up
Baseline assessment
Patient demographic information including NHS num-
ber, date of birth, gender, date of admission, type of ad-
mission, category of medical condition (orthopaedics
and trauma, oncology, critical care and other conditions)
and ethnicity will be recorded.
Patient risk profiles and key risk factors will be re-
corded through clinical assessment and completion of
the Braden scale and PURPOSE-T including baseline
skin status, localised skin pain on pressure areas, activ-
ity and mobility status, sensory perception, diabetes,
conditions affecting macro and micro circulatory func-
tion, nutrition, skin moisture, friction and shear, PU
history, height and weight (self-report or notes where
available) and duration and size of ulcer and photo-
graph (if consented) for patients with a pre-existing cat-
egory 2 PU [9, 15, 16, 18].
PU prevention interventions pre-randomisation will be
recorded including mattress type, turning frequency and
seating provision.
Patients will be asked to complete quality of life ques-
tionnaires, which include: 12-item Short Form (SF-12),
Pressure Ulcer Quality of Life-Utility Index (PUQoL-UI)
[15] and EuroQol-5D 5 level (EQ-5D-5L); with the latter
two by proxy for patients who lack capacity. In addition
PUQoL-Prevention (P) data, an adapted version of
PUQoL [19], will be collected in a subset of patients.
It is expected that the baseline assessment and ran-
domisation will take place on the same day.
Treatment phase follow-up assessment
Treatment phase follow-up assessments will be undertaken
up to a maximum of 60 days post randomisation. These
will be undertaken by a trained CRN/RHCP twice weekly
from randomisation up to 30 days, then once weekly up to
60 days. The treatment phase is defined as the period from
randomisation to discharge, transfer to an ineligible facility,
when the patient is considered no longer at high risk
(considered at each assessment), reaching 60 days,withdrawal or death, whichever is soonest. No longer at
high risk is defined as no Category 1 or above PU on
any skin site AND no localised skin pain on a healthy,
altered or Category 1 skin site, AND improved mobility
and activity (Braden activity score 3 or 4 AND Mobility
score 3 or 4) [20].
Patients will have a skin assessment, including pain
and photography (if consented) of Category 2 and
above ulcers where present and not previously photo-
graphed, and PU prevention interventions recorded.
Mattress compliance and technical faults will be col-
lected daily. At weeks 1 and 3 post randomisation,
healthcare resource utilisation, and quality of life ques-
tionnaires SF-12 [21], PUQoL-UI and EQ-5D-5L [22]
will be completed (PUQoL-UI and EQ-5D-5L by proxy
for patients lacking consent); the PU-QoL-P will again
be administered to a subset of patients.
Following the end of the treatment phase patients will
receive care in line with routine standard practice.
Post-treatment phase follow-up assessment
At 30 days post end of the treatment phase, a final skin
assessment (including photography if selected) will be
undertaken at the patient’s home or care facility by a
member of the research team. This assessment will only
be at 90 days if the end of the treatment phase has a
duration of 60 days. Should the patient be discharged,
considered as no longer at high risk, or transferred to
an ineligible facility prior to 90 days then the final
follow-up assessment will be scheduled to take place at
30 days post the date of: discharge, no longer at risk or
transfer.
Healthcare resource utilisation, and quality of life ques-
tionnaires (SF-12, Pressure Ulcer Quality of Life-Utility
Index (PUQOL-UI) and EQ-5D-5L; and PU-QoL-P in a
subset of patients) will be completed.




The primary endpoint is time to developing a new
Category 2 or above PU from randomisation to 30
days from the end of the treatment phase (maximum
of 90 days).
Secondary endpoints
The secondary endpoints will be determination of the
following:
 Time to developing a PU of Category 3 or above
from randomisation to trial completion
 Time to developing a PU of Category 1 or above
from randomisation to trial completion
Fig. 2 Schedule of enrolment, interventions, and assessments
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randomisation to trial completion
 Health-related quality of life using SF-12 and
PU-QoL-P instruments
 Incremental cost-effectiveness of APM compared to
HSF from the perspective of the health and social
care sectors using EQ-5D-5L and health and social
care resource utilisation questionnaire
 Mattress changes during the treatment phase
 Adverse events
Skin assessments
Skin will be assessed by trained CRNs/RHCPs using the
international PU classification (NPUAP/EPUAP 2014). At
baseline and each visit post randomisation, all skin sites at
risk of PU development (sacrum, right and left buttocks,
hips, heels and elbows), will be assessed by the CRN/RHCP
and confirmed as normal skin (0), incontinence-associated
dermatitis (IAD), alteration to intact skin (A) or the pres-
ence of a PU. PUs when present will be classified and re-
corded using the National Pressure Ulcer Advisory Panel/
European Pressure Ulcer Advisory Panel (NPUAP/EPUAP)classification as Category 1–4 or unstageable [6]. Reasons
will be recorded for skin sites that are unable to be assessed.Blinding
As it is not possible to blind patients or the TVT, a val-
idation substudy, using photography with blinded central
review and expert clinical assessment of the skin sites by
an independent member of the team, will be conducted
to assess any bias in the reporting of Category 2 or
above PUs. Two approaches are being implemented: To
assess the risk of over-reporting of the ulcer, the CRN/
RHCP who is not independent will photograph each
Category 2 or above PU at first observation. To assess
risk of under-reporting, 10% of patients are randomised
for expert clinical assessment and photography of two
skin sites by an independent member (if the patient has
at least one PU then a photograph will be taken at a
maximum of one PU skin site and one healthy skin site).
A standardised photography process will be imple-
mented to ensure a consistent approach is used across
all centres when taking and transferring photographs;
Fig. 3 Double triangular group sequential design
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undertaken by expert clinical nurse specialists.
Sample size
A maximum of 588 events i.e. patients developing a new
Category 2 or above PU, corresponding to 2954 patients, are
required for the study to have 90% power for detecting a dif-
ference of 5% in the incidence of Category 2 or above PUs
between APM and HSF, assuming an incidence rate of 18%
on APM [13, 23] and 23% on HSF [15, 16, 23, 24] (corre-
sponding to a hazard ratio of 0.759), two-sided significance
level of 5%, and accounting for 6% loss to follow-up [13].
The PU incidence for APM of 18% was estimated on the
intention-to-treat (ITT) population for the completed PRES-
SURE trial [13], the PURPOSE Pain Cohort study [15, 16] and
the trial reported by Vanderwee [23], and hence the sample
size estimate incorporates the effect of any non-compliance.
The sample size accounts for multiplicity in the interim
analyses using Lan-DeMets α and β spending functions [25].
PU incidence rates cannot be estimated accurately for
the HSF and the maximum sample size estimate is based
on the detection of the smallest clinically relevant differ-
ence of 5% (clinical opinion). If the difference is >5%
then the trial will have sufficient power to stop early
having demonstrated superiority (or inferiority) of the
APM; if the difference is <5% then the trial is likely to
stop early for futility.
The approximate sample size for the PUQoL-P sub-
study will be 500 patients.
A maximum of approximately 1653 photographs are
expected for the central blinded review, which will en-
able kappa to be estimated to within a precision of at
least ±0.044 (corresponding to the half width of the 95%
CI), assuming 65% of photographs are of Category 2 or
above PUs and kappa ≥0.5.
Statistical analysis
Statistical analysis plans for the interim and final ana-
lyses will be finalised and signed off before any data ana-
lyses are conducted.
All analyses will be on an ITT basis where patients will
be analysed according to treatment group randomised to
receive. A per protocol population will also be defined,
which will include all eligible randomised patients ac-
cording to the treatment received but will exclude major
protocol violations as agreed by the clinical members of
the Trial Management Group (TMG).
Interim analysis and stopping rules
The group sequential design provides an efficient design
through the possibility of early stopping ([26, 27]
As this is a group sequential design, the trial will have
a maximum of three planned analyses with unequally
spaced reviews at event-driven coherent cut-points:1. The first analysis conducted after 300 events
corresponds to the earliest time point at which the
trial can be stopped for demonstrating
overwhelming evidence of efficacy or futility, and
also corresponds to the minimum number of events
required for conducting the economic evaluation.
The futility boundaries are constructed as
non-binding in order for the Data Monitoring and
Ethics Committee (DMEC) to overrule a decision of
stopping early for futility in the event that a futility
boundary is crossed. In the event of the DMEC
recommending that the trial is stopped for futility
using the pre-defined stopping criteria, an expected
value of sample information analysis will be
undertaken to assess the value of additional sample
information on the effectiveness parameter, to
establish whether continuing the trial would be
valuable from the NHS decision-makers’ perspective.
If the decision to stop is overruled, the stopping
boundaries will be adjusted using the “buy-back
alpha” approach [28].
2. The second analysis, conducted after 445 events
corresponds to the number of expected events
required for trial termination under futility
(with 434 corresponding to the number of events
required for demonstrating superiority or inferiority
of APM to HSF).
3. The final review will be conducted after 588 events
have occurred.
The double triangular group sequential design is shown
in Fig. 3. The efficacy and futility stopping boundaries are
defined using Lan-DeMets α and β spending functions,
which provide conservative stop/continue criteria at the
interim analyses.
At each interim analysis, the primary analysis of the
primary endpoint, time to developing a Category 2 or
above PU, will be conducted on both the ITT and per
protocol population. The test statistic for the treatment
effect from the Cox proportional hazards model (after
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valid), adjusting for the minimisation factors and covari-
ates specified in the primary endpoint analysis section
below, will be used to test for a difference between treat-
ment groups. The hazard ratio for the treatment effect
and adjusted confidence interval corresponding to the
nominal p value will be presented.
Interim analyses will be presented to the DMEC who will
then advise the Trial Steering Committee (TSC) if there is
proof beyond reasonable doubt that the trial should be
stopped in accordance with the planned stopping rules.
Primary endpoint analysis
Primary analysis
A Cox proportional hazards model (after confirming the
proportional hazards assumption is valid) will be fitted
to the primary endpoint, with adjustment for the mini-
misation factors: healthcare setting, PU status and con-
sent, and the following covariates: presence of pain on a
healthy, altered or Category 1 PU skin site, conditions
affecting peripheral circulation and treatment group.
Centre will be assessed for inclusion as a random effect.
The hazard ratio for the estimate of the treatment effect
and adjusted confidence interval corresponding to the
nominal p value will be presented. Patients who do not
develop a Category 2 or above PU during the treatment
phase or by 30 days post treatment follow-up will be cen-
sored at the date of their last evaluable skin assessment.
Kaplan-Meier estimates of the probability of patients
developing a Category 2 or above PU over 90 days in
each group and adjusted confidence intervals corre-
sponding to the nominal p value will be presented.
Moderator and mediator analyses
Potential predictors of time to developing Category 2 or
above PU will be explored by assessing potential pre-
dictor by treatment group interactions in the model. In
addition, the relationship between potential moderator
and mediator variables (including length of stay, time on
allocated mattress, patient turning, and use of specialist
cushions, heel protectors and protective dressings) and
treatment effect will be modeled.
Secondary endpoint analysis
The secondary endpoints, time to developing a PU of at
least Category 1, and time to developing a PU of at least
Category 3, will be analysed using Cox proportional hazards
modelling (after confirming the proportional hazards
assumption is valid) adjusting for the minimisation factors
and same covariates as for the primary endpoint analysis
and treatment group.
A Cox proportional hazards model (after confirming
the proportional hazards assumption is valid) will be
fitted to the outcome time to healing of pre-existingCategory 2 PUs; covariates fitted in the primary endpoint
model will be assessed for inclusion and treatment group.
A substudy analysis will be performed to examine the
PU-QoL-P instrument responsiveness; effect sizes [29]
and standardised response means (SRM) [30] before and
after mattress allocation will be estimated. Independent t
tests will be conducted to assess the ability of the PU-
QoL-P instrument to distinguish between patients whose
PUs deteriorate or heal. Subject to the results of the
instrument responsiveness analysis, QoL domains and
subscales for the SF-12 and PU-QoL-P will be compared
between treatment groups using multilevel repeated mea-
sures modeling allowing for time, mattress type, mattress
type by time interaction, adjusting for baseline QoL, pa-
tient and patient by time interaction as random effects.
Adverse events and serious adverse events classified as
related to the mattress, resulting from administration of
any research procedures, and falls and device-related
events during the treatment phase and follow-up will be
listed and summarised by treatment group.
Assessment of the feasibility of the blinded outcome
assessment
To assess the feasibility of the blinded outcome assess-
ment using photography and blinded endpoint review, a
sensitivity analysis of the primary endpoint analysis will be
conducted to assess the risk of over-reporting of category
2 or above PUs, replacing the primary endpoint for those
patients with a Category 2 or above PU with the assess-
ment made in the blinded central endpoint review. To as-
sess under-reporting of the development of Category 2 or
above PUs, cross-tabulations, kappa and prevalence- and
bias-adjusted kappa (PABAK) statistics will summarise the
extent of agreement of reporting of Category 2 PU status
at skin sites between the independent member of the
team, CRN/RHCP and photography assessments.
Missing data
The pattern of missing data over time and by treatment
group will be assessed. If assumed to be missing at ran-
dom (MAR), multiple imputation will be considered. If
the data are thought to be missing not at random
(MNAR) then appropriate methods such as pattern mix-
ture models will be explored.
Economic evaluation
Within-trial economic evaluation
The expected costs and outcomes will be estimated for
each treatment group up to 90 days post randomisation;
based upon the observed outcomes and resource utilisa-
tion collected during the trial. The outcome measure used
in the primary economic evaluation will be the quality-
adjusted life year (QALY), using utilities derived from the
EQ-5D-5L. A secondary analysis will use PUQoL-UI, a
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PU-QoL measure [19]. The resource use data collection
will focus on those incurred by the NHS including length
of stay in hospital, use of hospital outpatient facilities, con-
tact with community-based healthcare services and utilisa-
tion of supported living such as care and nursing homes.
Unit costs will be obtained from national databases such
as the NHS Reference costs [31] and the Personal Social
Services Research Unit (PSSRU) costs of health and social
care [32]. Other costs will be estimated in consultation
with the finance departments of centres recruiting to the
trial. Within-trial QALYs and resource cost for a sub-
sample of trial patients will be estimated. Due to the short
time horizon for the within-trial analysis, discounting will
not be required. Non-parametric bootstrap will be used to
estimate the expected costs and outcomes for each group
and the associated incremental cost-effectiveness ratio for
APM versus HSF. The results of the bootstrap will be used
to construct a cost-effectiveness acceptability curve
(CEAC), using a range of values of willingness to pay per
incremental QALY.
Long-term cost-effectiveness of APM versus HSF in
prevention of PUs in high-risk patients
A longer-term cost-effectiveness analysis of APM versus
HSF will be undertaken. The model will use the perspec-
tive of the NHS and outcomes measured using quality-
adjusted life years (QALYs). The model will adapt the
structure proposed by Padula et al [33]. Data from the
trial will be used for transitions between states, costs
and utilities. This will include, but not be limited to,
probabilities of developing and first and second PU, dis-
charge from hospital and re-admission to hospital; utility
values based on the EQ-5D-5L data and costs including
daily costs for each type of mattress and extra costs for
treatment of PUs. For model parameters for which data
could not be collected within the trial we will follow rec-
ommended best practice in identifying and synthesising
the best available evidence in the literature [34, 35].
Costs and outcomes will be discounted at 3.5% p.a. in
line with the NICE recommendations [34]. A probabilis-
tic sensitivity analysis will be undertaken and the results
will be reported as a CEAC. The CEAC represents the
probability an intervention is cost-effective for a range of
willingness to pay per incremental QALY threshold
values. Subgroup analyses will be undertaken where ana-
lyses of the clinical outcome data suggest a substantial
difference in absolute benefit from in a priori identifiable
groups.
In the event of an early stopping signal for futility; to
assess the value of continuing with the trial from the
NHS decision-making perspective, via an expected value
of sample information analysis, to inform the delibera-
tions of the DMEC [36].Data management
Data will be monitored for quality and completeness.
Missing data will be chased until it is received or con-
firmed as not available. Data received will be linked-
anonymised and entered onto a secure database at
LICTR in accordance with the 1998 Data Protection
Act. Photographs taken will be transferred immediately
by secure email to LICTR and stored on a secure data-
base. Once confirmation of receipt is received by the
clinical CRN/RHCP, the photographs will immediately
be deleted from the camera.
Trial governance
The TMG, comprising the Chief Investigator, co-
investigators, patient representative and project team
will meet monthly and is responsible for the clinical set-
up, ongoing management and for the interpretation of
results. The DMEC, with independent Chair, will meet
at least annually to review trial progress, safety and to
monitor the overall incidence rate, and following each
interim analysis. The TSC, with independent Chair, will
meet 6 monthly and provide overall supervision of the
project, including trial progress, adherence to protocol
and consideration of new information.
Discussion
The double triangular group sequential trial provides an
efficient design through the possibility of early stopping
for demonstrating either futility of the trial or superiority
of either mattress. The trial optimises the potential for
producing robust clinical evidence on the effectiveness
of two commonly used mattresses in clinical practice
earlier than in a conventional fixed design. A fixed de-
sign with the same parameters would require 554 events.
Although conducting a group sequential trial increases
the maximum sample size required compared to a con-
ventional fixed design, these stopping boundaries will
also allow for an increased chance of stopping early. In
addition, the trial utilises an early primary endpoint,
time to developing a Category 2 or above PU to a max-
imum of 90 days, and therefore early stopping can be
assessed in a timely manner.
On the other hand, a potential limitation of having an
early endpoint is that PUs developing over a longer time
horizon will be missed, however as PUs generally de-
velop quickly in this patient population [13] this would
affect a minority of patients, and it is was therefore con-
sidered that the duration of follow-up is optimum to
allow early assessment of superiority of either mattress
or futility of the trial.
Group sequential trials with a time to event primary
endpoint require close monitoring of the overall event
rate in order to plan when an interim analysis will be
conducted. A benefit of this close monitoring allows the
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the assumptions specified in the original trial design,
thereby allowing the trial design to be modified prior to
an interim analysis if required.
Stopping boundaries provide statistical guidance to the
DMEC on the recommendations for stopping the trial
early; however factors including patient safety, cost-
effectiveness and other information external to the trial
will also need to be considered in order to make a fully
informed decision on whether or not to continue [28].
As this is a pragmatic trial, the operational specifica-
tions for both HSF and APM have been developed and
defined in the PRESSURE 2 Mattress Specification
Guideline, rather than product-specific mattresses for all
trial patients, as this increases the generalisability of the
trial findings to the NHS. There are also research costs
advantages as the trial does not require the purchasing
of specified products.
Having a blinded assessment of outcome measures is a
key consideration in reducing the risk of assessment
bias. In this study we will assess the feasibility of having
a blinded outcome assessment using photography with a
blinded independent central review undertaken by clin-
ical nurse specialists. During photograph review ses-
sions, the central panel will be unaware of whether the
photographs are to assess under- or over-reporting of
Category 2 or above PUs, thereby further mitigating the
risk of assessment bias.
A further benefit of this design is the inclusion of the
substudy to assess responsiveness of the PU-QoL-P tool
at the first planned interim analysis, and which will pro-
vide a sufficient number of patients to allow a validation
of this psychometric property of the tool.
Findings from the trial will inform future clinical prac-
tice in the management of patients at high risk of devel-
oping PUs.Trial status
The first patient was randomised on 14 August 2013. As
of 13 April 2016, 1501 patients have been randomised.
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